Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Скачать или смотреть Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025

  • Sona Nanotech Inc
  • 2025-10-23
  • 323
Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025
  • ok logo

Скачать Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025 бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025 или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

  • Информация по загрузке:

Cкачать музыку Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025 бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео Discussing First-In-Human THT Cancer Therapy Study Results - Webinar - 20 Oct 2025

Sona announced the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona’s Targeted Hyperthermia Therapy (“THT”). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early feasibility study. Under the study protocol, patients had up to four tumors treated with Sona’s THT on days one and eight of the study. By day 15, 8/10 patients experienced a significant clinical response to treatment with a majority (6/8) showing no detectable residual melanoma in representative, biopsied tumors, and two patients showing no response.

About
About Sona Nanotech (CSE: SONA | OTCQB: SNANF) is a leading biotechnology company that specializes in the development and commercialization of unique gold nanorod technology. Sona Nanotech also pioneers the field of targeted hyperthermia, leveraging their gold nanorod technology to selectively deliver heat to specific cancer cells, offering a promising approach for cancer treatment with minimal damage to surrounding healthy tissues. Through their innovative platform, Sona is revolutionizing various sectors, including diagnostics, life sciences, and pharmaceuticals. With a focus on enhancing accuracy, sensitivity, and speed, their products offer significant advantages over traditional methods, enabling faster and more efficient testing and analysis. Sona Nanotech's commitment to continuous innovation and collaboration positions them as a key player in the advancement of nanotechnology applications, ultimately aiming to improve healthcare outcomes and contribute to scientific advancements on a global scale.

**********
Investor Presentation
►Download here: https://www.sonanano.com/investor-pre...
**********
Visit our website:
► https://sonanano.com/
**********
Get the latest news and investor updates in your inbox ***
►Subscribe here: https://www.sonanano.com/newsletter-s...
**********
Read more about our Technology
►Learn more: https://www.sonanano.com/technology-o...
**********

Follow us on Social Media:
► Linkedin:   / sona-nanotech-ltd  
► Twitter:   / sonananotech  
► Instagram:   / sona_nanotech  
► Facebook:   / sonananotechinc  
► Subscribe to our YouTube Channel: https://www.youtube.com/channel/UCCK3...

Комментарии

Информация по комментариям в разработке

Похожие видео

  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]